Premium
Antibody Response After Single H1N1 Influenza Vaccine in Chronic Dialysis Patients
Author(s) -
Azak Alper,
Huddam Bülent,
Kocak Gülay,
Altas A Basak,
Duranay Murat,
Korukluoglu Gülay
Publication year - 2013
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2012.01133.x
Subject(s) - medicine , peritoneal dialysis , hemodialysis , vaccination , dialysis , virus , pandemic , kidney disease , antibody titer , h1n1 influenza , intensive care medicine , titer , immunology , disease , covid-19 , infectious disease (medical specialty)
The first influenza pandemic of this century happened through a rapid spread of a novel swine‐derived H1N1 influenza virus. Vaccines are produced in order to avoid the infection. Children and other high risk groups are highly recommended for vaccination due to the high probability of contracting the virus. Chronic kidney disease patients were also accepted as a risk group and vaccination of all patients undergoing hemodialysis or peritoneal dialysis was recommended. The results of H1N1 influenza virus vaccine on patients receiving hemodialysis and peritoneal dialysis are analyzed. Antibody titers of both hemodialysis and peritoneal dialysis patients were elevated after vaccination. Peritoneal dialysis patients responded better.